Replies to post #3452 on Idenix Pharmaceuticals (IDIX)

[go seek]

Agree... but expect $12-$15/share
would not follow until other significant news.
i.e., subsequent HCV and /or HIV clinical results or buyout.

[vladster]

I agree with you. The last two analysts upgrades were to $7 and $9 a share based upon the IDX184 data that was presented.

There are a lot of "ifs" here but if IDIX can pull off a decent partnership deal that will include the other HCV drug with the ultimate combo goal then $12 to $15 is not pie-in-the-sky.

At the very least, I would expect that if a good combo deal gets announced the stock should at least get into the $8 to $10 range and then once the analysts digest the information and up their targets we would at least see a longer term up trend targeting $15.